(Q38012529)

27 August 2017

Epidemiology and management of Kawasaki disease (English)

1 reference

27 August 2017

1 reference

Rae S M Yeung

2

0 references

author name string

Nadia J C Luca

series ordinal

1

1 reference

27 August 2017

1 May 2012

1 reference

27 August 2017

1 reference

27 August 2017

72

1 reference

27 August 2017

1029-1038

1 reference

27 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.2165/11631440-000000000-00000

27 August 2017

0 references

cites work

Diagnosis, treatment, and long-term management of Kawasaki disease

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Kawasaki syndrome in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Kawasaki disease in England: ethnicity, deprivation, and respiratory pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Epidemiological features of Kawasaki disease in Korea, 2006-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Kawasaki disease in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Kawasaki disease in Australia, 1993-95.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

The immunologic effects of IVIG in Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Does abciximab promote coronary artery remodeling in patients with Kawasaki disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Risk factors for nonresponse to therapy in Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Infliximab treatment for refractory Kawasaki syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Infections and Kawasaki disease: implications for coronary artery outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Recognition of a Kawasaki disease shock syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Macrophage activation syndrome in the acute phase of Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631440-000000000-00000

Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children

21 January 2018

1 reference

12 December 2020

Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?

1 reference

12 December 2020

High-dose intravenous gammaglobulin for Kawasaki disease

1 reference

12 December 2020

Intravenous immunoglobulin for the treatment of Kawasaki disease in children

1 reference

12 December 2020

Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale

1 reference

12 December 2020

Kawasaki disease: effect of treatment on coronary artery involvement

1 reference

12 December 2020

Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii.

1 reference

12 December 2020

High-dose intravenous gammaglobulin for Kawasaki disease

1 reference

12 December 2020

Kawasaki disease in Hong Kong, 1994 to 2000.

1 reference

12 December 2020

Case-control study of giant coronary aneurysms due to Kawasaki disease: the 19th nationwide survey

1 reference

12 December 2020

TNF- Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease

1 reference

12 December 2020

Repeated systematic surveillance of Kawasaki disease in Ontario from 1995 to 2006

1 reference

12 December 2020

Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007.

1 reference

12 December 2020

Initial intravenous gammaglobulin treatment failure in Kawasaki disease

1 reference

12 December 2020

Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin.

1 reference

12 December 2020

Salicylate for the treatment of Kawasaki disease in children

1 reference

12 December 2020

10.2165/11631440-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22621692

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22621692